Outset Medical wins VA contract to improve dialysis care for veterans

SAN JOSE, Calif.–(BUSINESS WIRE)–Outset Medical, Inc. (Nasdaq: OM) (“Start”) today announced that the Department of Veterans Affairs Strategic Acquisition Center (SAC) Procurement Office has awarded a nationwide contract to sell the Tablo® Hemodialysis System from society in the 106 VA hospitals of the US

VA medical facilities across the United States provide dialysis care to 35,000 veterans. While Tablo is already deployed in some of these facilities, the new five-year contract will allow VA centers to acquire consoles to send veterans home and expand use in the acute setting. The award provides for an indefinite quantity of services and goods during the indefinite delivery indefinite quantity (IDIQ) award contract. As one of three centralized contracting entities within the VA, SAC has been tasked with creating superior supply solutions that deliver on the VA’s promise to veterans.

“Our Honored Veterans deserve to receive the most advanced dialysis care possible, and it is our great privilege to support them through the SAC Contract for Hemodialysis Care,” said Leslie Trigg, President and Chief direction of Outset. “This partnership with the VA will further our mission to bring a technology-based, patient-centered approach to dialysis in both the acute and home settings.”

Outset offers the Tablo hemodialysis system for kidney patients, which is a one-of-a-kind, FDA-cleared enterprise solution for use across the continuum of care, from hospital to home. A smart, connected device, Tablo features two-way communication with the cloud, allowing treatment data to be sent electronically and allowing doctors to remotely monitor patients so they feel connected to their medical team while being comfortable at home.

Outset, through SDV Medical, has been awarded the contract opportunity for SLED Dialysis, HD Integrated HHD/Water Purification and HD Integrated IHD/Water Purification:

  • SLED, or Slow Low Efficiency Dialysis, with Tablo makes it possible to offer adaptive dialysis specific to a patient’s needs. Existing dialysis machines provide either continuous 24-hour treatment or short (3-4 hour) treatment, but lack the clinical flexibility to offer intermediate treatment durations. In contrast, Tablo offers clinicians the flexibility to align treatment time with the patient’s clinical needs.

  • HHD, or Home Hemodialysis, allows the patient to perform dialysis treatments at home, safely and efficiently, using Tablo, which only requires a standard electrical outlet and tap water to operate.

  • IHD, or intermittent hemodialysis, allows traditional dialysis treatment over a period of 3 to 4 hours in a chronic or acute context.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo hemodialysis system, cleared by the FDA for hospital-to-home use, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be used across the continuum of care, allowing dialysis to be administered anytime, anywhere, by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with two-way wireless data transmission and a proprietary data analysis platform fueling a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Forward-looking statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s strategy, expectations, plans and outlook regarding the SAC contract and the expected results and benefits of the contract. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied by such statements. . These risks and uncertainties include the risks described in the Risk Factors section of Outset’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and should not be relied upon unduly. Outset disclaims any obligation to update these forward-looking statements.

More Stories
Initiative will help vulnerable areas of the Gulf Coast cope with rising sea levels